Compare iShares MSCI Hong Kong ETF (EWH) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Novartis AG — how do they compare? iShares MSCI Hong Kong ETF trades at $22.2, while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG pays a 3.02% dividend while iShares MSCI Hong Kong ETF pays none, and Novartis AG is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals.
| EWH | NVS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $168.62 |
52-Week Low | $20.66 | $119.31 |
Market Cap | — | $298.18B |
Enterprise Value | — | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH trades at $22.71 with a 0.98% daily gain, showing neutral technical signals overall. The ETF tracks Hong Kong equities, with recent momentum in the Hang Seng Index providing support. Moving averages indicate bullish momentum while oscillators remain neutral. The fund declared a $0.35 dividend payable in June 2026, offering income potential alongside capital appreciation.
Outlook remains balanced with technical strength offset by valuation concerns. Key opportunities include Hong Kong market recovery and technology sector momentum, while risks involve Asian market volatility and geopolitical tensions. The neutral technical stance suggests waiting for clearer directional signals before establishing new positions.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
